Momenta could be first to benefit from Obama plan to push for biogenerics
Small US firm Momenta Pharmaceuticals may beat Israel's Teva to become the first company to launch a biogeneric drug in the USA.
The eight-year old firm, which has yet to turn a profit, specializes in complex sugars and other mixtures and enjoys a close relationship with the Food and Drug Administration that analysts believe could allow it to get a generic version of Sanofi-Aventis' Lovenox (enoxaparin) onto the market before its competitors.
The Cambridge, Massachusetts-based company used its analytical technology last year to help the FDA identify the lethal contaminant in batches of heparin from China (Marketletter April 21, 2008).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze